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Abstract
Background: The third stage of labour refers to the period between birth of the baby and
complete expulsion of the placenta. Some degree of blood loss occurs after the birth of the baby
due to separation of the placenta. This period is a risky period because uterus may not contract
well after birth and heavy blood loss can endanger the life of the mother. Active management of
the third stage of labour (AMTSL) reduces the occurrence of severe postpartum haemorrhage by
approximately 60–70%. Active management consists of several interventions packaged together
and the relative contribution of each of the components is unknown. Controlled cord traction is
one of those components that require training in manual skill for it to be performed appropriately.
If it is possible to dispense with controlled cord traction without losing efficacy it would have major
implications for effective management of the third stage of labour at peripheral levels of health care.
Objective: The primary objective is to determine whether the simplified package of oxytocin 10
IU IM/IV is not less effective than the full AMTSL package.
Methods: A hospital-based, multicentre, individually randomized controlled trial is proposed. The
hypothesis tested will be a non-inferiority hypothesis. The aim will be to determine whether the
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simplified package without CCT, with the advantage of not requiring training to acquire the manual
skill to perform this task, is not less effective than the full AMTSL package with regard to reducing
blood loss in the third stage of labour.
The simplified package will include uterotonic (oxytocin 10 IU IM) injection after delivery of the
baby and cord clamping and cutting at approximately 3 minutes after birth. The full package will
include the uterotonic injection (oxytocin 10 IU IM), controlled cord traction following observation
of uterine contraction and cord clamping and cutting at approximately 3 minutes after birth. The
primary outcome measure is blood loss of 1000 ml or more at one hour and up to two hours for
women who continue to bleed after one hour. The secondary outcomes are blood transfusion, the
use of additional uterotonics and measure of severe morbidity and maternal death.
We aim to recruit 25,000 women delivering vaginally in health facilities in eight countries within a
12 month recruitment period.
Management: Overall trial management will be from HRP/RHR in Geneva. There will be eight
centres located in Argentina, Egypt, India, Kenya, Philippines, South Africa, Thailand and Uganda.
There will be an online data entry system managed from HRP/RHR. The trial protocol was
developed following a technical consultation with international organizations and leading
researchers in the field.
Expected outcomes: The main objective of this trial is to investigate whether a simplified
package of third stage management can be recommended without increasing the risk of PPH. By
avoiding the need for a manual procedure that requires training, the third stage management can
be implemented in a more widespread and cost-effective way around the world even at the most
peripheral levels of the health care system. This trial forms part of the programme of work to
reduce maternal deaths due to postpartum haemorrhage within the RHR department in
collaboration with other research groups and organizations active in the field.
Trial Registration: ACTRN12608000434392
Background
The third stage of labour refers to the period between birth
of the baby and complete expulsion of the placenta. Some
degree of blood loss occurs after the birth of the baby due
to separation of the placenta. This period is a risky period
because uterus may not contract well after birth and heavy
blood loss can endanger the life of the mother.
The third stage of labour is managed differently around
the world. Over the years two management packages,
known as 'active management' and 'expectant manage-
ment' emerged. The primary aim of active management is
to reduce postpartum blood loss as a preventive interven-
tion. In active management (AMTSL) a number of inter-
ventions are applied in combination while the expectant
management represents a more hands-off style with those
interventions used in AMTSL withheld. AMTSL has been
defined in various ways and current international defini-
tion comprises three components: administration of an
uterotonic soon after delivery of the baby; controlled cord
traction; and uterine massage after delivery of the placenta
[1]. Active management of the third stage of labour
(AMTSL) reduces the occurrence of severe postpartum
haemorrhage by approximately 60–70% [2].
In previous active versus expectant trials the cord was
clamped as soon as possible usually within one minute.
However, trials of cord clamping timing have shown ben-
eficial effects on newborn haematological indices leading
to the recommendation to clamp the cord at around 3
minutes although the effects on the mother are unknown
[3].
The WHO PPH Prevention Guidelines published in 2007
recommended AMTSL defined as the use of oxytocin 10
IU IM/IV after birth, cord clamping at around 3 minutes
when the uterus contracts and controlled cord traction.
There were no recommendations related to the use of
uterine massage in this guideline.
Unfortunately, the relative contribution of the compo-
nents of AMTSL to the overall reduction in blood loss is
not clearly known. Understanding the contribution of the
components of AMTSL to the overall effect in reducing the
incidence of haemorrhage could have major program-
matic significance since some components require train-
ing while others require an efficient drug procurement
and utilization system [4]. At the same time the probabil-
ity of interaction between AMTSL components should be
kept in mind.
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These considerations led to a technical consultation of sci-
entists working in the field of postpartum haemorrhage
research in December 2007 to discuss work on a research
project to evaluate the effects of different components of
AMTSL. Such research is important and timely because
some components such as the uterotonic and controlled
cord traction may not be feasible in all settings and it is
worthwhile evaluating a more simple package with fewer
components.
Systematic reviews of effects of AMTSL components
Uterotonic
The uterotonic component of AMTSL seems to be impor-
tant for the reduction in blood loss after delivery [5]. Two
trials compared oxytocin to nothing without other active
management components practiced [6,7] and one trial
compared oxytocin to nothing with other active manage-
ment components practiced in both groups [8]. Oxytocin
used at 5–10 IU seemed to reduce the risk of severe post-
partum haemorrhage although the other components
were not well described.
Controlled cord traction
Cord traction was introduced into obstetric practice by
Brandt (1933) and Andrews (1940) by the so-called
Brandt-Andrews maneuver. The aim is to facilitate the
delivery of a placenta that is already separated. In 1962 the
term controlled cord traction (CCT) was introduced which
aims to facilitate the separation of the placenta once the
uterus contracts [9]. In performing CCT placental separa-
tion is not waited and once the uterus contracts the CCT
is initiated. The third stage is usually completed in less
than 10 minutes when CCT is used.
There is concern by clinicians, based on teachings from
their pre-service education that traction on the cord prior
to placental separation may lead to maternal complica-
tions such as separation of the cord from the placenta and
uterine inversion. There is not a large body of direct evi-
dence for or against effects of controlled cord traction in
isolation [10].
CCT requires training to acquire this manual skill. Evalu-
ation of CCT component is important because if it does
not add any beneficial effects it can be dropped from the
AMTSL package with important programmatic implica-
tions.
Uterine massage
Uterine massage is used following delivery in various
forms. Between delivery of the baby and the placenta a
birth attendant will often put his/her hand over the
uterus to ensure that there is no undiagnosed twin, to
assess if the uterus is contracting and may rub the uterus
to stimulate contraction. The Cochrane review on active
versus passive management does not refer to the use of
uterine massage as part of AMTSL whereas the FIGO/
ICM statement on AMTSL does include uterine massage
as part of AMTSL. Evidence that massage contributes to a
reduction in blood loss would provide evidence to sup-
port the use of this intervention with simple instruc-
tions.
The National Institute for Health and Clinical Excellence
of the United Kingdom published comprehensive guide-
lines on intrapartum management on 26 September 2007
http://www.nice.org.uk/nicemedia/pdf/IPCNICEGuid
ance.pdf and has made no reference to uterine massage.
A small pilot trial (n = 200) conducted in Assiut, Egypt,
used 'sustained uterine massage' started after delivery
applied every 10 minutes and continued for 60 minutes.
The findings are promising, since women receiving mas-
sage had less blood loss > 500 ml and received less addi-
tional uterotonics than women not receiving uterine
massage [11]. In the two surveys conducted by Prevention
of Postpartum Hemorrhage Initiative (POPPHI) massage
before placental delivery was practiced in about one third
of all deliveries. In the same surveys massage after placen-
tal delivery was used in 80–90% of women although it
was not possible to observe how long after delivery the
massage was continued [12].
Williams Obstetrics states "massage is not employed but
the fundus is frequently palpated to make certain that the
organ does not become atonic and filled with blood from
placental separation". In the United States and some other
countries, palpating the uterus and massaging if "soft" for
the first few hours after childbirth is considered standard
of care [13]. In many countries however, no well-defined
massage protocol exists. A systematic review to evaluate
the effects of sustained uterine massage from the time of
birth of the baby currently contains very little evidence to
guide practice [14].
Other interventions
One intervention that has recently been included in
AMTSL package is delayed cord clamping. There is evi-
dence that delayed cord clamping increases newborn hae-
matological indices in the short term and also has
beneficial effects of reduced intraventricular haemorrhage
when applied to preterm infants. However, there is almost
no evidence on maternal effects especially whether it
increases the blood loss.
Other third stage interventions include squeezing the
uterus from the fundus to expel the placenta (Credé
maneuver) [15], placental cord drainage, umbilical vein
injection and variations in timing, dose, and route of
above discussed components.
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Rationale for selecting the experimental intervention
An important aspect of AMTSL components is that one
cannot assume that each component has no interaction
with others. Such interactions could occur for single, dou-
ble or triple components. The implication is that even if
an intervention may not be (as) effective when individu-
ally applied it may have effect together with another com-
ponent. For example, oxytocin and massage could act
synergistically.
The relative importance of all of these uncertainties and
the feasibility of evaluating the effects of one or more of
the components were discussed in detail at the technical
consultation referred above in December 2007. The eval-
uation of two components namely CCT and uterine mas-
sage after placental delivery was given priority. The
feasibility of evaluating both interventions in one trial
was discussed in detail. Different epidemiological designs
such as three-arm and 2 × 2 factorial design were consid-
ered. Evaluating more than one component in a single
trial posed particular difficulties. Such difficulties origi-
nated from the nature of the intervention(s) (manual pro-
cedures being difficult to mask) and the low incidence of
the primary outcome measure. The implications of these
two factors were resorting to cluster or cross-over cluster
designs with added complexity and large sample sizes. At
the end of the consultative process evaluation of a package
that does not include controlled cord traction was
regarded as the highest priority research question among
all discussed. The main reason for this conclusion is that
currently, the global scale up of AMTSL is limited to those
settings where skilled birth attendants are available largely
because controlled cord traction (CCT) requires clinical
skills training. Considerable training investments are
needed to enable health providers to do CCT correctly and
safely.
The presence of a skilled birth attendant is essential in
every childbirth. Birth attendants are required for not only
basic care during the first and second stage of labour but
also in the third stage when haemorrhage risk is greatest
and also for the immediate care of the newborn. We aim
to identify the relative effect of one component that
requires manual skill training. In the most peripheral
points of the health system the availability of health per-
sonnel with skills to implement the full AMTSL package
may be more difficult to ensure in some settings. There-
fore, evaluation of whether a simplified package without
CCT is non-inferior to the full AMTSL package has both
clinical and public health importance. The simplified
package is also less intrusive for the mother.
If it were possible to demonstrate the non-inferiority of a
simplified form of AMTSL, dispensing with CCT, it would
greatly reduce programme costs associated with training,
and enable the intervention to be used by lower level pro-
viders, especially in out-of-hospital settings.
We therefore put forward the hypothesis that a simplified
package comprising oxytocin 10 IU IM/IV (with or with-
out uterine massage) is as effective as the full AMTSL pack-
age.
Objective
The primary objective is to determine whether the simpli-
fied package of oxytocin 10 IU IM/IV, without CCT, is not
less effective than the full AMTSL package with regard to
reducing blood loss ≥ 1000 ml in the third stage of labour.
The hypothesis will be that of non-inferiority within a
margin of 0.45 to 0.50%. If this hypothesis is demon-
strated, the simplified package without CCT could be
adopted, with the advantage of not requiring training to
acquire the manual skill to perform this task.
Study design
This will be a hospital-based, multicentre, individually
randomized non-inferiority controlled trial.
Each woman will be randomized to receive either the full
(AMTSL) package or the simplified package. The blinding
of the intervention will not be possible because the com-
parison includes a manual procedure.
Interventions
In order to overcome the variations in the actual practice
of AMTSL a working definition was discussed and agreed
upon during the technical consultation.
Experimental arm: Simplified package
The simplified package will include;
• Uterotonic
Oxytocin 10 IU IM. Oxytocin will be administered as soon
as possible after birth preferably within one minute. If a
woman has an IV line oxytocin can be administered
through the IV line by slow injection.
• Cord clamping
Cord will be clamped following observation of a uterine
contraction either manually or visually. For practical pur-
poses this is estimated to be around 1–3 minutes. It is rec-
ommended to clamp the cord close to the perineum.
• Placental delivery
Cord traction is omitted. Placenta should be delivered
passively by aid of gravity and maternal effort. The car-
egiver should observe the placental separation and as the
placenta delivers it should be held in two hands and gen-
tly turned so that the membranes do not tear off.
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• Uterine massage
No uterine massage is recommended before placental
delivery. After placental delivery the uterus will be rubbed
and any clots expressed. For a period of two hours the
uterus will be massaged gently until it contracts and this
procedure will be repeated every 15 minutes. It is
acknowledged that not all centres will be able to imple-
ment this component. Each centre will decide before the
trial begins whether the uterine massage component will
be implemented or not.
Standard intervention arm: Full AMTSL package
The full package will include:
• Uterotonic
Oxytocin 10 IU IM. Oxytocin will be administered as soon
as possible after birth preferably within one minute. If a
woman has an IV line oxytocin can be administered
through the IV line by slow injection.
• Cord clamping
Cord will be clamped following observation of a uterine
contraction either manually or visually. For practical pur-
poses this is estimated to be around 1–3 minutes. It is rec-
ommended to clamp the cord close to the perineum.
• Placental delivery
Placenta will be delivered by controlled cord traction
immediately after cord clamping and cutting. The cord
will be gently pulled while applying counter traction to
the uterus with the other hand. As the placenta delivers it
should be held in two hands and gently turned so that the
membranes do not tear off.
• Uterine massage
No uterine massage is recommended before placental
delivery. After placental delivery the uterus will be rubbed
and any clots expressed. For a period of two hours the
uterus will be massaged gently until it contracts and this
procedure will be repeated every 15 minutes. It is
acknowledged that not all centres will be able to imple-
ment this component. Each centre will decide before the
trial begins whether the uterine massage component will
be implemented or not.
The two intervention packages will differ only in placental
delivery technique. If the umbilical cord has been
clamped early because of newborn indication cord trac-
tion should be applied only after the uterus has contracted
as above.
Outcome measures
The primary outcome measure is blood loss of 1000 ml or
more at one hour and up to two hours for women who
continue to bleed after one hour. Blood collection will be
made using the calibrated drape BRASSS-V® and measured
from delivery to one hour following delivery or up to two
hours if bleeding continues [16].
Secondary outcomes are;
• blood transfusion,
• the use of additional uterotonics to treat PPH
• blood loss 500 ml or more
• postpartum maternal haemoglobin (in centres where
feasible)
• maternal death
• manual removal of placenta,
• additional surgical procedures (e.g. hysterectomy, liga-
tion of vessels)
• composite outcome of maternal death or severe morbid-
ity (admission to intensive care unit, hysterectomy, blood
loss of two liters or more, uterine inversion, near miss
event as defined in the manual of operations)
• initiation of breastfeeding
• side effects such as nausea and abdominal pain
Once the cord is clamped and cut the drape will be placed
under the woman's buttocks and blood loss measurement
will begin. The blood loss measurement will continue for
one hour regardless of whether the woman is kept in the
delivery room or moved elsewhere. If the bleeding contin-
ues beyond one hour the blood loss measurement will
continue until two hours postpartum.
Side effects will be recorded by the researcher. Any side
effect requiring treatment will be regarded as an adverse
event and a separate form will be filled.
Serious adverse events will be recorded in special forms
and will be returned by the local investigators to the trial
coordination unit within 24 hours.
Study population
All women expecting to deliver vaginally at the participat-
ing hospitals will be potentially eligible. Women will be
approached primarily during antenatal care and early
labour for consent for participation except under the fol-
lowing circumstances;
1. Advanced first stage of labour (> 6 cm cervical dilata-
tion)
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2. Women who are too distressed to give consent regard-
less of cervical dilatation or phase of labour. Such evalua-
tion will be made by the clinician in charge of the care of
the woman.
3. Minors without a guardian
4. Planned caesarean section
5. If the birth is considered an abortion according to local
limits
6. Women with twins or higher order multiple gestations
7. Women who are not capable of giving consent due to
other health problems such as obstetric emergencies (e.g.
eclampsia) or mental disorder.
Women receive AMTSL regardless of whether they are at
high or low-risk for haemorrhage. Therefore all women
will be eligible for participation according to the excep-
tions mentioned above.
Methods
Generation of allocation sequence
The random allocation sequence will be generated cen-
trally at WHO Headquarters using computer generated
random numbers. Randomization will be to two groups
and stratified by country. Blocking with randomly varying
groups of 6–8 will be used to restrict randomization
within the strata.
Random allocation technique and allocation concealment
Allocation of the random generated sequence will be by
consecutively numbered envelopes. Allocation conceal-
ment will be achieved by using sealed opaque envelopes.
Allocation will take place during second stage when vagi-
nal delivery is imminent. Once the envelope is opened the
name of the woman will be entered on the log file with
the envelope number and that woman is enrolled in the
trial.
Rationale for the non-inferiority hypothesis and for sample 
size estimation
The objective of this trial is to show 'non-inferiority' of the
simplified package' compared to the full AMTSL package.
As such, while superiority would be an added bonus it is
not expected and is probably not plausible since the
experimental intervention has fewer interventions.
In the conventional superiority trial, the aim is to deter-
mine whether one intervention is superior to another, for
example, whether uterotonic is superior to nothing. By
contrast, in a non-inferiority trial, the aim is to determine
whether an alternative intervention with certain advan-
tages is similar to a gold standard. The full AMTSL package
represents the gold standard management strategy for
reducing blood loss in the third stage of labour. In order
to evaluate the effectiveness of a simplified package with
fewer components that package has to be compared to the
full package to see whether t is "non-inferior" to the gold
standard [17].
Because proof of exact equality is impossible, a pre-stated
margin of non-inferiority (Δ) for the difference in effec-
tiveness has to be defined. The choice of the non-inferior-
ity margin can be made using clinical assessment, which
is to a certain extent arbitrary, and needs consensus
among different stakeholders. A technique which has
been proposed [17] to establish the non-inferiority mar-
gin is to look at the effect of the gold standard, in this case
the full AMTSL, compared with placebo in historical
(past) trials, in this case the expectant management. A rea-
sonable criterion is to preserve 80% of the benefit of the
full AMTSL package (considered as 100%) over expectant
management (considered as 0%). Preserving a higher per-
centage (say 90%) will push the sample size calculations
very high while a smaller percentage (say 50%) may not
be considered acceptable.
Estimates of blood loss ≥ 1000 ml (severe PPH – sPPH)
with active and passive management were taken from the
literature. In addition, unpublished data from several
ongoing WHO studies where postpartum blood loss is
measured were obtained. Based on those data, a 1.5% risk
of blood loss of 1000 ml with full active management was
considered realistic and appropriate.
The expectant management sPPH rate was more difficult
to estimate because the data was only available from ear-
lier published trials and blood loss estimation methods
and the actual expectant management method differed
between trials. Values between 3.0 to 4.0% are considered
realistic and used for sample size estimations.
Table 1 includes different scenarios for the calculation of
sample size, obtained by varying the sPPH rate with
expectant management (3.0 to 4.0%) and varying the %
retained effect (70% to 80%), assuming a fixed 1.5%
sPPH rate for the full AMTSL package. These different sce-
narios result in different choices of the margin of non-
inferiority Δ. The total sample size required for a non-infe-
riority test at the 2.5% level using a two-sided 95% confi-
dence interval and a power of 80% is shown, as well as the
power obtained for fixed sample sizes of 20,000 and
25,000.
A trial of 22,908 women will have 80% power to show
non-inferiority of the simplified package within 0.45% of
the full AMTSL package sPPH rate (i.e. less than 1.95%
Reproductive Health 2009, 6:2 http://www.reproductive-health-journal.com/content/6/1/2
Page 7 of 10
(page number not for citation purposes)
sPPH rate), with a level of significance of 2.5% (Table 1,
row 1). The estimates from the centres that have expressed
interest in participating in the trial indicate that approxi-
mately 20,000–25,000 women can be recruited in a 12
months recruitment period. These centres have collabo-
rated with WHO before and have experience in third stage
trials.
Type of data and data collection procedure
The trial will be conducted in the labour ward of mater-
nity facilities. All women with anticipated vaginal delivery
will be eligible. During the trial period information on the
total number of births in the facility will be collected to
monitor the recruitment efficiency. Ideally, the participat-
ing centres should enroll women 24 hours a day. How-
ever, such recruitment may not be possible at all centres.
The main data collection will be during the immediate
postpartum period but women will be followed up until
discharge from the hospital to record any additional inter-
ventions and complications that may occur. Once the
bleeding stops and the woman is ready for transfer to the
postnatal ward the researcher will fill the data collection
form. After discharge the data collection forms will be
completed and the form data will be entered on to the
online system. The online data entry will be either at the
hospital or country level depending on local capacity.
Analysis plan
The main analysis will be on an intention-to-treat princi-
ple with comparisons made between the 'simplified' and
'full' AMTSL packages for primary and secondary out-
comes. An alternative to the ITT analysis (non-ITT analy-
sis, sometimes called 'per-protocol'), that excludes
patients not on their intended treatment and/or those
who are not protocol-compliant in any other way could
bias the trial in either direction, depending on which
patients are thus excluded. In non-inferiority and equiva-
lence trials, performing non-ITT analysis in addition to
ITT analysis is desirable as a protection from the increase
in type I error risk.
We expect only a small number of protocol deviations
because the personnel involved in the study will receive
intensive and continuous training and because the trial
will be closely monitored by trial investigators and peri-
odically by a Data Monitoring Committee that will look
at protocol deviations. Thus, the decrease in power due to
exclusions of protocol deviations will be minimal. Table 1
shows that for the proposed sample size, the power is
higher than the usually required 80%.
There may be deviations from the trial protocol if the
baby's condition requires urgent action. In such situations
the cord may be clamped and cut immediately after birth
of the head and if the caregiver is involved in the resusci-
tation the timing of placental delivery may differ (this
could be in either direction). We would expect this devia-
tion to be equally distributed in the two groups. A second
type of deviation could occur if a woman who has earlier
given consent and randomly allocated to one group with-
draws her consent after randomization. The withdrawal of
consent after random allocation should be extremely rare
since the random allocation will be made when vaginal
delivery is imminent We have looked at earlier trials
where expectant management was used (because expect-
ant management omits controlled cord traction) and did
not find any suggestion that there was a compliance prob-
lem with omission of CCT. Nevertheless, the sample size
calculation has a margin of additional power as men-
tioned in table 2 to ensure that such protocol deviations
do not have a negative impact on the conclusions[17]
The actual management of third stage of labour will be
recorded in all women to enable the analysis mentioned
above.
Comparisons will be expressed as relative risks and risk
differences with 95% confidence intervals. The analysis
will be stratified by site, and if there is heterogeneity
between the sites for any of the results possible causes of
heterogeneity will be explored. In the presence of hetero-
geneity, the results will not be combined in a single sum-
mary estimate (or pooled estimate). In the absence of
heterogeneity at the 5% level, the results will be com-
bined.
The primary analysis will follow the following scheme for
interpretation (Figure 1):[18] If the lower limit of the 95%
confidence interval lies to the right of the non-inferiority
Table 1: Sample size scenarios
Blood loss ≥ 1000 
ml with full amtsl
Blood loss ≥ 1000 
ml with Expectant
Estimated impact 
of Full AMTSL
Proportion (of full 
AMTSL effect) 
retained by the 
simplified package
Δ (Difference to 
exclude to claim 
equivalence)
Total N for 80% 
Power
Power with total 
N = 20,000
Power with total 
N = 25,000
1.5 3.0 1.5 0.7 0.45 22,908 75% 83%
1.5 3.5 2.0 0.75 0.50 18,555 83% 90%
1.5 4.0 2.5 0.8 0.50 18,555 83% 90%
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Table 2: CONSORT recommendations in the protocol – Checklist for non-inferiority and equivalence trials. Items 1 through 12[17]
Paper section and topic Item Descriptor Reported on section
TITLE & ABSTRACT 1 How participants were allocated to interventions (e.g., 
"random allocation", "randomized", or "randomly 
assigned"), specifying that the trial is a non-inferiority or 
equivalence trial.
Title in cover page. Summary: section 1
INTRODUCTION Background 2 Scientific background and explanation of rationale, 
including the rationale for using a non-inferiority or 
equivalence design.
2 and 3. In particular, see 2.1.5, two last 
paragraphs for rationale for non-inferiority
METHODS Participants 3 Eligibility criteria for participants (detailing whether 
participants in the non-inferiority or equivalence trial are 
similar to those in any trial(s) that established efficacy of the 
reference treatment) and the settings and locations where 
the data were collected.
4.3 and 4.4.3
Interventions 4 Precise details of the interventions intended for each 
group detailing whether the reference treatment in the non-
inferiority or equivalence trial is identical (or very similar) to 
that in any trial(s) that established efficacy, and how and 
when they were actually administered.
4.1
Objectives 5 Specific objectives and hypotheses, including the 
hypothesis concerning non-inferiority or equivalence.
3
Outcomes 6 Clearly defined primary and secondary outcome 
measures detailing whether the outcomes in the non-
inferiority or equivalence trial are identical (or very similar) to 
those in any trial(s) that established efficacy of the reference 
treatment and, when applicable, any methods used to 
enhance the quality of measurements (e.g., multiple 
observations, training of assessors).
4.2
Sample size 7 How sample size was determined detailing whether it was 
calculated using a non-inferiority or equivalence criterion and 
specifying the margin of equivalence with the rationale for its 
choice. When applicable, explanation of any interim 
analyses and stopping rules (and whether related to a non-
inferiority or equivalence hypothesis).
4.4.3
Randomization – Sequence 
generation
8 Method used to generate the random allocation 
sequence, including details of any restrictions (e.g., 
blocking, stratification)
4.4.1
Randomization – Allocation 
concealment
9 Method used to implement the random allocation 
sequence (e.g., numbered containers or central 
telephone), clarifying whether the sequence was 
concealed until interventions were assigned.
4.4.2
Randomization – Implementation 10 Who generated the allocation sequence, who enrolled 
participants, and who assigned participants to their 
groups.
4.4.2
Blinding (masking) 11 Whether or not participants, those administering the 
interventions, and those assessing the outcomes were 
blinded to group assignment. If done, how the success of 
blinding was evaluated.
4 (last sentence before 3.1)
Statistical methods 12 Statistical methods used to compare groups for primary 
outcome(s), specifying whether a one or two-sided 
confidence interval approach was used. Methods for 
additional analyses, such as subgroup analyses and 
adjusted analyses.
4.4.3 & 4.5
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margin (Δ) the experimental intervention will be declared
"inferior" (situation H). Situations A-D indicate non-infe-
riority with respect to the pre-stated margin Δ. Situations
E-G are inconclusive, although E and F are not likely to
occur because the trial size guarantees sufficient power. If
the results are inconclusive regarding the non-inferiority
hypothesis and the whole 95% confidence interval lies to
the right of zero (situation G), it will be concluded that
the limited package was statistically significantly worse
according to a superiority hypothesis.
Interim analysis
A Data Monitoring Committee (DMC) with no direct
involvement in the trial will be appointed. The role of the
DMC will be to deal with any ethical issues that may arise
while the trial is in progress, and to scrutinize an interim
analysis. An interim analysis will be conducted to be
reviewed by the DMC after the completion of the first
5,000 participants. A second interim analysis will be con-
ducted after 10,000 – 15,000 women are recruited.
Interim analyses will be masked to trial investigators but
not to DMC members. Reporting and handling of adverse
events will be in accordance with the Good Clinical Prac-
tice guidelines.
Stopping the trial
The DMC will be asked to give advice regarding stopping
the trial if they have proof beyond doubt of an important
advantage or disadvantage for one of the treatment
groups, and they consider that the results are likely to
affect clinical practice. For the main outcome results of the
interim analyses, the DMC will base their recommenda-
tion on a superiority hypothesis two-sided stopping rule:
if one of the treatments is significantly superior to the
other, they will consider to stop the trial. The Haybittle-
Peto rule for the α-spending function will be used to
determine the level of significance at the two interim anal-
yses and at the final analysis.
Stratified analysis
It is likely that some centres will practice uterine massage
and some not. A stratified analysis will be conducted of
the primary outcome by the use of uterine massage, to
assess the interaction of uterine massage by CCT. How-
ever, it is likely that such an analysis will be underpow-
ered. The use of uterine massage will also be considered as
a potential confounding variable.
Duration of the project
It is anticipated that the recruitment into the study in the
centres can be completed in approximately 12 months.
Recruitment will begin around November-December
2008 after trial procedures have been tested and materials
have been procured and distributed to the study sites.
(Calibrated drape BRASS-V and oxytocin).
Expected outcomes of the study
The main objective of this trial is to investigate whether a
simplified package of third stage management can be rec-
ommended without increasing the risk of PPH. By avoid-
ing the need for a manual procedure that requires
training, the third stage management can be implemented
in a more widespread and cost-effective way around the
world even at the most peripheral levels of the health care
system.
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